CEVEC Pharmaceuticals GmbH

CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing

CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients

CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA(R) AAV manufacturing technology in Gene Therapy

CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies

CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy

CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA(R) Technology in gene therapy

CEVEC AND RZNOMICS SIGN LICENSE AGREEMENT FOR THE USE OF CAP(R) TECHNOLOGY IN MANUFACTURING OF ADENOVIRAL VECTORS

CEVEC Announces the Launch of the ELEVECTA(R) Platform – the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors

CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use

CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications

CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform

CEVEC strengthens its Scientific Advisory Board with the appointment of gene therapy specialist J. Fraser Wright, Ph.D.

CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP(R)Go technology

CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP(R)Go technology-derived TGF-ß1 for ex vivo cell culture

CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference

CEVEC has been granted a new CAP(R)Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach

CEVEC licenses CAP(R)Go technology in the field of veterinary vaccines

CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA

CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologies

CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP(R) technologies in North America

CEVEC’s CAP(R)GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications

CEVEC intensifies its marketing activities, presenting at various renowned scientific conferences in Europe and the US

CEVEC and Beckman Research Institute of City of Hope enter into a cooperation and license agreement on CEVEC’s proprietary CAP(R)GT technology

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies

CEVEC strengthens team to execute rapid growth strategy

CEVEC and CellGenix sign collaboration and license agreement for CEVEC’s proprietary CAP(R)Go technology